Blair William & Co. IL Sells 4,815 Shares of Moderna, Inc. (NASDAQ:MRNA)

Blair William & Co. IL lowered its position in Moderna, Inc. (NASDAQ:MRNA) by 15.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,500 shares of the company’s stock after selling 4,815 shares during the period. Blair William & Co. IL’s holdings in Moderna were worth $3,147,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Ashton Thomas Private Wealth LLC bought a new stake in Moderna during the 2nd quarter worth about $26,000. Cedar Wealth Management LLC grew its stake in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares during the last quarter. Westside Investment Management Inc. acquired a new stake in shares of Moderna in the first quarter valued at approximately $32,000. Family Firm Inc. bought a new position in Moderna in the 2nd quarter worth approximately $33,000. Finally, Rise Advisors LLC lifted its holdings in Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after buying an additional 286 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Trading Down 3.4 %

Moderna stock opened at $65.69 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The stock has a 50-day simple moving average of $90.07 and a 200 day simple moving average of $110.96. The stock has a market capitalization of $25.18 billion, a P/E ratio of -4.19 and a beta of 1.67. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The company had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. During the same period in the previous year, the company posted ($3.62) EPS. The firm’s revenue for the quarter was down 29.9% compared to the same quarter last year. Analysts expect that Moderna, Inc. will post -9.52 earnings per share for the current year.

Insiders Place Their Bets

In other news, President Stephen Hoge sold 15,000 shares of the stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $121.12, for a total value of $1,816,800.00. Following the transaction, the president now directly owns 1,442,089 shares of the company’s stock, valued at $174,665,819.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO James M. Mock sold 689 shares of the business’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the completion of the sale, the chief financial officer now directly owns 7,269 shares in the company, valued at approximately $859,486.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Stephen Hoge sold 15,000 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $121.12, for a total value of $1,816,800.00. Following the transaction, the president now owns 1,442,089 shares in the company, valued at approximately $174,665,819.68. The disclosure for this sale can be found here. Insiders sold a total of 93,158 shares of company stock valued at $11,167,312 over the last ninety days. 15.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently commented on MRNA. Jefferies Financial Group downgraded Moderna from a “buy” rating to a “hold” rating and dropped their target price for the stock from $120.00 to $65.00 in a research report on Friday, September 13th. The Goldman Sachs Group cut their target price on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. JPMorgan Chase & Co. cut shares of Moderna from a “neutral” rating to an “underweight” rating and lowered their price target for the stock from $88.00 to $70.00 in a research report on Friday, September 13th. William Blair restated a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 target price on shares of Moderna in a report on Thursday. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $100.44.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.